Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Noriyasu Usami, MD, Shingo Iwano, MD, Kohei Yokoi, MD

Brain Radionecrosis Treated with Bevacizumab in a Patient with Resected Squamous Cell Carcinoma of the Lung Jordi Remon, MD, Cécile Le Péchoux, MD, Caroline.

Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long- term Survivor with Metastatic Non–Small-Cell Lung Cancer Kristin N.

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

David T. Cooke, MD, Dennis J. Zheng, Karen A. Peterson, NP, Royce F

Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous.

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

Electronic Updates for JTO Readers

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Muhammad Umair Khawar, MD, Bhaskar Bhardwaj, MD, Himanshu Bhardwaj, MD

Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M–Mutant Leptomeningeal Lung Adenocarcinoma Christine Cordova, MD, Andrew S. Chi,

Estrogen Receptor (ER) and Epidermal Growth Factor Receptor (EGFR) as Targets for Dual Lung Cancer Therapy: Not Just a Case? Monica Giovannini, MD, Carmen.

A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non– Small-Cell Lung Cancer Josette Biya, MD, Caroline Caramella, MD, Colin.

Atypical Pleuropulmonary Tuberculosis Mimicking a Malignant Disease

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Erlotinib Accumulation in Brain Metastases from Non-small Cell Lung Cancer: Visualization by Positron Emission Tomography in a Patient Harboring a Mutation.

Effect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma Nader Abedallaa, MD, Lise Tremblay, MD, Charlotte.

Multiple Pulmonary Chondromas in a Young Female Patient: A Component of Carney Triad Gui-Bin Qiao, MD, PhD, Wei-Sheng Zeng, MD, Li-Jun Peng, MD, Wen-Zhao.

Successful Treatment with Erlotinib after Gefitinib-Induced Severe Interstitial Lung Disease Masayuki Takeda, MD, PhD, Isamu Okamoto, MD, PhD, Chihiro.

A Case of Invasive Mucinous Pulmonary Adenocarcinoma with a CD74-NRG1 Fusion Protein Targeted with Afatinib Parneet K. Cheema, MD, MBiotech, FRCPC Journal.

Vipul Pareek, MD, Mary Welch, MD, Elizabeth Ravera, RN, Richard L

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient Jordi Remon, MD, Anas Gazzah, MD, Benjamin Besse,

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Retroperitoneal Metastasis from Lung Adenocarcinoma Mimics Retroperitoneal Fibrosis Akihiro Nishiyama, MD, Hiroshige Yoshioka, MD, PhD, Satoshi Ikeo,

Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity? Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,

Non–Small-Cell Lung Cancer with HER2 Exon 20 Mutation: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment Gerald S. Falchook, MD,

Osteoblastic Bone Lesions Developing During Treatment with Erlotinib Indicate Major Response in Patients with Non-small Cell Lung Cancer: A Brief Report

Jennifer L. Dallas, MD, Michael A. Jantz, MD, Judith L

Nasion Swelling as the Presenting Symptom of Lung Adenocarcinoma

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Drug Interaction Between Complementary Herbal Medicines and Gefitinib

The Number of Pulmonary Metastases: Influence on Practice and Outcome

S768I Mutation in EGFR in Patients with Lung Cancer

Noriyasu Usami, MD, Shingo Iwano, MD, Kohei Yokoi, MD

Multiple Pulmonary Nodules in an Elderly Woman

Pulmonary Metastasectomy in Breast Cancer

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Two Generations of Light/Never-Smokers With Advanced Adenocarcinoma of the Lung with Durable Responses to Erlotinib Nathan A. Pennell, MD, PhD, Lihong.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Recursive Partitioning Analysis Groups II–III Brain Metastases of Non-small Cell Lung Cancer: A Phase II Randomized Study Comparing Two Concurrent Chemoradiotherapy.

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Report of Eight Recent Cases of Locally Advanced Primary Pulmonary Artery Sarcomas: Failure of Doxorubicin-Based Chemotherapy Nicolas Penel, MD, PhD,

Bronchioloalveolar Carcinoma Presenting as Chronic Progressive Pulmonary Infiltrates in a Woman with HIV: A Diagnosis Worth Making Todd M. Erickson,

European Lung Cancer Conference (ELCC) 2016 Organisation

Andreas Rimner, MD, Kenneth E. Rosenzweig, MD

Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer Judith Elizabeth Carser, MB, BCh, MRCR, Yvonne Jane Summers,

Tetsuzo Tagawa, MD, Miyuki Takasu, MD, Teruyoshi Ishida, MD

Metastatic Lung Cancer to the Pancreas

S-1 Treatment for Chemorefractory Thymic Carcinoma

Collaterals Journal of Thoracic Oncology

Intrathoracic Desmoid Tumor: Brief Report and Review of Literature

Pleural Metastases of Malignant Melanoma

Journal of Thoracic Oncology

David Garfield, MD Journal of Thoracic Oncology

Efficacy of Erlotinib for Brain and Leptomeningeal Metastases in Patients with Lung Adenocarcinoma Who Showed Initial Good Response to Gefitinib Tatsuya.

Use of Fluoroscopy During Endobronchial Ultrasonography for Transbronchial Lung Biopsies of Peripheral Lung Lesions Daniel Steinfort, MBBS, Louis Irving,

A Review of First-Line Treatment for Small-cell Lung Cancer

Robert Comis, MD, The Passing of a “Lung Man”

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD, Jean-Charles Soria, MD, PhD Journal of Thoracic Oncology Volume 3, Issue 6, Pages 677-679 (June 2008) DOI: 10.1097/JTO.0b013e3181757a8b Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 A, MRI demonstrated no cranial lesion growth but did reveal leptomeningeal contrast enhancements (see arrows); (B) after 9 weeks of erlotinib treatment, significant regression of the leptomeningeal contrast enhancements was observed. Journal of Thoracic Oncology 2008 3, 677-679DOI: (10.1097/JTO.0b013e3181757a8b) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 A, A chest CT scan showed an increase in the size of the pulmonary lesion, and a new peripheral lesion; (B) after 9 weeks of erlotinib treatment, there was significant regression of the pulmonary lesion. Journal of Thoracic Oncology 2008 3, 677-679DOI: (10.1097/JTO.0b013e3181757a8b) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions